semaglutide teens Wegovy use among U.S. up 50% as obesity crisis worsens Weight-loss drug semaglutide recommended for

Effects typically last 34 months

Schmiesing J, Storch S, Drfler AC, Schweizer M, Makrypidi-Fraune G, Thelen M, et al

P.D'LimaD

Scientists from the WHO recently wrote: The approval of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of obesity creates potential for a transformation of the whole health system that could halt and reverse the global obesity pandemic through prevention and effective integrated management. Growing crisis South Africa is grappling with dual diabetes and obesity epidemics, on top of the HIV and TB epidemics, but is not responding effectively, resulting in high obesity and diabetes-related deaths